• We offer a comprehensive repertoire of cell biology based methods & models to delineate the molecular action of NCEs or novel formulations. Our assay development team can customize a range of in vitro, ex vivo and in vivo cell based models to determine the key cellular pathways determining the pharmacology of the lead molecules. The methodologies are designed to evaluate NCEs, Phytochemicals, or differentiated formulations. These mechanistic studies may be useful for selection of pharmacodynamic endpoints One or more of the following strategies may be undertaken to profile the molecule under investigation


    Metabolic Disease



    In Vitro Cosmetic Screens




  • Our preclinical In Vivo research platform are currently focused in the therapeutic areas of Oncology, Metabolic Disease, Inflammation, Hair Biology, Derma Pathology, Fertility, Gastrointestinal


    Metabolic Disease


    Invitro Cosmetic Screens




  • A technically experienced team of scientists at DRF carry out in vitro ADME and in vivo Pharmacokinetic/ Toxicokinetics along with a well supported bioanalytical group to expedite the discovery process for the sponsor. The services offered include -





    • Toxicology Department of Dabur Research Foundation (DRF) has several years of experience and expertise to design and conduct toxicity studies with various route of administration viz., oral, dermal, Intravenous, subcutaneous, intraperitoneal, intramuscular etc. such as for Pharma, BioPharma, Agrochemicals, Specialty Chemicals in accordance with International Guidelines viz., ICH, EMEA, WHO, FDA, OECD, EU and OPPTS and National guidelines such as Schedule Y, CIB and AYUSH (CCRAS) and the studies are conducted in compliance with Good laboratory practices (GLP ).

      • Maximum Tolerable Dose (MTD).
      • Dose Range Finding (DRF).
      • Single Dose Toxicity studies.
      • Repeated dose sub-acute Toxicity studies (14, 28 days).
      • Subchronic Toxicity Study (90 days)
      • Chronic Toxicity studies (180 days to 1 year)
      • Skin, mucous membrane, and eye irritation studies.
      • Skin Sensitization Studies
      • Local Tolerance test
      • Specific Toxicity study
      • Neurotoxicity study
      • Carcinogenicity study
      • Combined Chronic/carcinogenicity study
      • Reproductive /developmental Toxicity
      • Biocompatibility studies on medical devices as per ISO 10993.
      • Genotoxicity (e.g. In vivo MNT and In vitro CA)


      The pathology laboratory has two functional areas i.e. histopathology and clinical pathology. The histopathology section performs the necropsy, tissue weighing and preservation, tissue processing and pathologist evaluation whereas clinical pathology carries out hematology, clinical chemistry and, coagulation and urine analysis which is mandatory in general toxicity evaluation. 

  • Background

    Adult human mesenchymal stem cells (hMSC) are rare fibroblast-like cells capable of differentiating into a variety of cell types including bone, cartilage, and fat cells. The International Society for Cell Therapy (ISCT) has recommended a specific cell surface signature for MSCs. Conventional surface markers used to define hMSCs are CD73, CD90, and CD105 positive and CD14, CD19, CD34, CD45 and HLA-DR negative. Immunophenotype as measured by flow cytometry is among the criteria for identifying hMSC proposed by ISCT, which states that =95% of the hMSC population must express CD105, CD73, and CD90 and the same cells must lack (= 2% positive) expression of CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR. At DRF, MSCs can be characterized by immunophenotyping using flow cytometry (Guava flow cytometer).

    Test system Human MSCs (for batch characterization)
    • Receipt of MSCs cell suspension (batch wise)
    • Staining of cells fluorescent-tagged antibodies
    • Acquisition of stained cells on flow cytometer (Guava Technologies).
    End points
    Percentage expression of positive markers – CD105, CD73, and CD90 Percentage expression of negative markers - CD14, CD19, CD34, CD45 and HLA-DR

    • DRF biomarker estimation using Multiplex platforms is built around robust and well known Luminex xMAP technology. We can simultaneously detect different analytes offering significant cost saving and increased amount of information limited sample adding significant value to early discovery research. We perform multiplex study in diverse matrices such as serum, plasma, and tissue culture supernatants.
    • The various panels available with us include:
      • Human Inflammation Assays
      • Human MMP and TIMP Assays
      • Cytokine, Chemokine, and Growth Factor Assays- Human/Mouse/Rat
      • Diabetes, Metabolic, and Hormone Assays- Human/Mouse/Rat
      • Kidney Toxicity Assays- Human/Rat/Canine
      • Disease Research Assays-Human-Cancer; Cytokine; Acute phase; Isotyping
      • Cell Signaling Assays
      • Apoptosis Assays

  • Formulation experts at DRF use Quality-By-Design (QbD) tools to plan Design of experiments (DOE) along with risk assessment strategies. Our development approach supplemented with the right equipment, facilities and highly dedicated formulation development specialists helps you arrive at the optimal dosage form which is stable, scalable & compliant.

    Pre Formulation Studies

    Conventional Formulation Development

    Targeted Formulation Development

  • Coming Soon